"Furthermore, we plan to initiate trials with valbenazine this year in two new areas of interest, with registration phase studies in both the neurological and psychiatric indication."
"I'll begin with NBI-827104 or 104 for short. 104, a potent and highly selective T-type calcium channel antagonist, is currently enrolling patients in a Phase II study for epileptic encephalopathy with Continuous Spike and Wave during Sleep. 104 has the potential to expand into a range of other central nervous system disease areas. And we are moving forward with the initiation of a Phase II study in the first of these additional neurological indications this year."
"Turning now to NBI-921352, or simply 352...We also plan to initiate a Phase II study of 352 for the treatment of adult focal epilepsy this year. As a result, with our two precision medicine candidates, 104 and 352, we'll have trials underway in four distinct neurological disorders this year.
I missed all that - 3 molecules, 4 new indications, 2 new registrational trials (Ingrezza). Will look forward all the data in the coming year or two.